Corticotropin
- Generic Name
- Corticotropin
- Brand Names
- Acthar, Cortrophin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12427-33-7
- Unique Ingredient Identifier
- K0U68Q2TXA
- Background
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
- Indication
For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.
- Associated Conditions
- Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis
- Associated Therapies
- -
NeuroVoices: Martina Bebin, MD, MPA, on Critical Aspects of Infantile Spasms Awareness
Infantile spasms, an epileptic syndrome in children under 2, often accompanied by developmental delay, has a 0.25-0.42 per 1000 incidence rate. First-line treatments include adrenocorticotropic hormone, vigabatrin, and corticosteroids, though a third of patients remain uncontrolled. Infantile Spasms Awareness Week in December aims to support families and promote research. Early detection and diagnosis are crucial, with genetics, advanced imaging, and EEG playing significant roles. Emerging research focuses on genetic risk prediction, AI analysis of EEG data, and combined neuroimaging and EEG for a 3D brain view, all aiming for precision medicine and personalized treatment strategies.
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal
Neurocrine Biosciences' crinecerfont, targeting classic congenital adrenal hyperplasia (CAH), receives FDA Priority Review. If approved, it would be the first new CAH treatment in 70 years, offering a novel mechanism. CAH, caused by 21-hydroxylase gene mutations, affects hormone production in adrenal glands, with the US having the highest prevalence. Current treatments focus on managing symptoms, with EFMODY as the only approved drug in Europe. Emerging therapies like crinecerfont aim to normalize hormone levels and address the root cause of CAH.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath